Patients with multiple myeloma (MM) who relapse or become refractory to therapeutic agents tend to have a poor prognosis—often only a few months of survival. Within this group are patients that have been treated with five lines of therapy, referred to as penta-treated.
Here, we summarize a subanalysis by Oriol et al. published in Clinical Lymphoma, Myeloma and Leukemia on the results of the OPTIMISMM trial by frailty…
The Multiple Myeloma Hub virtual symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
Here, we summarize a multicenter, retrospective study conducted in France on the incidence and characteristics of infections following treatment with bispecific antibody therapy.
Here, we summarize a publication by Murugappan, et al. in Journal of Geriatric Oncology on a comparison between approaches to measuring frailty: the patient-reported frailty…
The Multiple Myeloma Hub virtual symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
On April 5, 2024, the U.S. FDA granted approval to idecabtagene vicleucel for the treatment of triple-class-exposed relapsed/refractory multiple myeloma after two or more prior…
We summarize a systematic review and meta-analysis by Akhtar et al. investigating the efficacy of CAR T-cell therapy and rates of immune-mediated toxicity in patients…
Here we summarize the rationale and latest clinical trial data investigating the use of cilta-cel in earlier lines of therapy in multiple myeloma.
During the EHA-EBMT 6th European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Paola Neri, University of Calgary, Calgary, CA. We asked, What factors…
Here, we summarize a report published by Guerrero et al. in Blood on predictors of unsustainable MRD-negativity in patients with multiple myeloma who are eligible…
